Amgen’s biosimilar Amgevita, an alternative to the world’s best-selling drug Humira, launched in European markets, the company announced Oct. 16. The launch follows a timeline for Amgevita’s release laid out by a settlement reached by the Thousand Oaks biotech giant and AbbVie, which owns the $16 billion per year Humira. U.S. sales of the biosimilar…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
